Cypherpunk Technologies Inc (CYPH)
Cypherpunk Technologies Inc. is a NASDAQ-listed common stock company based in Cambridge, Massachusetts. The business combines a privacy technology focus with a digital asset strategy centered on Zcash in the United States. Its activities include identifying, developing, investing in, acquiring, and building privacy-enhancing technologies, as well as accumulating digital assets such as Zcash. In parallel, the company continues to develop a clinical-stage biotechnology pipeline. That pipeline includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 and has completed a Phase 2 study in colorectal cancer, and FL-501, a monoclonal antibody targeting GDF-15 that is in preclinical development for cancer cachexia, hyperemesis gravidarum, pregnancy-related nausea and vomiting, and other conditions associated with aging and frailty. The company was incorporated in 2011 and adopted its current name in November 2025; it was previously known as Leap Therapeutics, Inc.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CYPH
|
$2.23
|
-40.1% Downside
|
Overvalued
|
$4.90
|
31.4% Upside
|
Undervalued
|
Great
|
0.0%
|
November 13, 2026
|
2.6x
|
402 M
|
353.8 M
|
0.0%
|
69.4%
|
61.9
|
2,401.1%
|
